By: Nicholas Simmonds, Emily Diable, Ladina Weitnauer, Natasha Singh, Imogen Felton, Rebecca Scott, Saraha Collins, Thomas Tobin, Rachel Robinson, Andrew Jones, Elaine Bowman, Amy Downes
A comprehensive review of maternal, obstetric and neonatal outcomes in pregnancies in females with cystic fibrosis (fwCF) following the introduction of Elexacaftor/Tezacaftor/Ivacaftor (ETI) therapy in a novel, dedicated CF-Maternal Health service.










